1178 related articles for article (PubMed ID: 10323388)
1. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
2. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
4. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
[TBL] [Abstract][Full Text] [Related]
5. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
8. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
[TBL] [Abstract][Full Text] [Related]
9. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
10. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus.
Cheetham TD; Holly JM; Baxter RC; Meadows K; Jones J; Taylor AM; Dunger DB
J Endocrinol; 1998 Apr; 157(1):81-7. PubMed ID: 9614361
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone.
Lee PD; Durham SK; Martinez V; Vasconez O; Powell DR; Guevara-Aguirre J
J Clin Endocrinol Metab; 1997 Jul; 82(7):2266-74. PubMed ID: 9215305
[TBL] [Abstract][Full Text] [Related]
12. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
[TBL] [Abstract][Full Text] [Related]
13. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3.
Gargosky SE; Wilson KF; Fielder PJ; Vaccarello MA; Guevara-Aguirre J; Diamond FB; Baxter RC; Rosenbloom AL; Rosenfeld RG
J Clin Endocrinol Metab; 1993 Dec; 77(6):1683-9. PubMed ID: 7505289
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
[TBL] [Abstract][Full Text] [Related]
15. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE
J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
[TBL] [Abstract][Full Text] [Related]
17. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.
Vaccarello MA; Diamond FB; Guevara-Aguirre J; Rosenbloom AL; Fielder PJ; Gargosky S; Cohen P; Wilson K; Rosenfeld RG
J Clin Endocrinol Metab; 1993 Jul; 77(1):273-80. PubMed ID: 7686916
[TBL] [Abstract][Full Text] [Related]
18. Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
Hanew K; Tanaka A
J Endocrinol Invest; 2001 Jan; 24(1):1-7. PubMed ID: 11227726
[TBL] [Abstract][Full Text] [Related]
19. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
